StreetInsider.com News Articles

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Strategic update on the progress and development of Molecure's key clinical projects in 2024

Fri, 28 Mar 2025 10:00:00 -0400

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A summary of the most important events of 2024:

Initiation of Phase II clinical trial (KITE) for OATD-01 in the treatment of pulmonary sarcoidosis at centers in the USA and Europe. Randomization and administration of OATD-01 or placebo to several patients with pulmonary sarcoidosis have been completed.
Efforts to initiate clinical development in MASH (Metabolism Associated Steatohepatitis) driven by strong preclinical results, independent research

Molecure and Ocean Biomedical (OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors

Tue, 15 Oct 2024 07:36:20 -0400

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors.
The Bio-dollar value of the agreement is approximately $32 million
Molecure S.A., a clinical stage biotechnology company, leveraging unique competencies in medical chemistry and biology to discover and develop first-in-class small molecule drugs

Molecure and Ocean Biomedical (OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors

Tue, 15 Oct 2024 07:36:20 -0400

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors.
The Bio-dollar value of the agreement is approximately $32 million
Molecure S.A., a clinical stage biotechnology company, leveraging unique competencies in medical chemistry and biology to discover and develop first-in-class small molecule drugs

Molecure and Ocean Biomedical (OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors

Tue, 15 Oct 2024 07:36:20 -0400

This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as well as inflammatory and fibrotic diseases, offering a novel approach to treating these conditions. In addition, the license covers a patent pending for a molecular screening test for further the continuation of the program and the development of new YKL-40 inhibitors.
The Bio-dollar value of the agreement is approximately $32 million
Molecure S.A., a clinical stage biotechnology company, leveraging unique competencies in medical chemistry and biology to discover and develop first-in-class small molecule drugs